RemeGen Co., Ltd. (9995.HK)
HKD 41.4
(8.8%)
HKD 41.4
(8.8%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 550.91 Million CNY | 128.93% |
| 2022 | -1.9 Billion CNY | -15.12% |
| 2021 | -1.65 Billion CNY | 35.66% |
| 2020 | -2.57 Billion CNY | -8441.7% |
| 2019 | 30.81 Million CNY | 5623.12% |
| 2018 | -558 Thousand CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.01 Billion CNY | 84.03% |
| 2024 Q2 | 1.59 Billion CNY | 69.84% |
| 2023 Q2 | -418.09 Million CNY | 63.86% |
| 2023 FY | 550.91 Million CNY | 128.93% |
| 2023 Q1 | -1.15 Billion CNY | 39.25% |
| 2023 Q4 | 550.91 Million CNY | 364.83% |
| 2023 Q3 | 118.51 Million CNY | 128.35% |
| 2022 Q2 | -2.5 Billion CNY | 33.69% |
| 2022 FY | -1.9 Billion CNY | -15.12% |
| 2022 Q4 | -1.9 Billion CNY | 3.91% |
| 2022 Q3 | -1.98 Billion CNY | 20.8% |
| 2022 Q1 | -3.77 Billion CNY | -128.1% |
| 2021 FY | -1.65 Billion CNY | 35.66% |
| 2021 Q2 | -1.4 Billion CNY | -150.79% |
| 2021 Q1 | 2.77 Billion CNY | 207.86% |
| 2021 Q4 | -1.65 Billion CNY | 0.0% |
| 2020 Q2 | -48.42 Million CNY | -137.4% |
| 2020 FY | -2.57 Billion CNY | -8441.7% |
| 2020 Q4 | -2.57 Billion CNY | 1.64% |
| 2020 Q3 | -2.61 Billion CNY | -5297.89% |
| 2020 Q1 | 129.48 Million CNY | 320.15% |
| 2019 Q3 | 617.29 Million CNY | 0.0% |
| 2019 FY | 30.81 Million CNY | 5623.12% |
| 2019 Q4 | 30.81 Million CNY | -95.01% |
| 2018 FY | -558 Thousand CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | 821.379% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 89.54% |